好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Prospective Characterization of Brain T2 Lesions Suggestive of Demyelination in Asymptomatic Patients diagnosed as Radiologically Isolated Syndrome
Multiple Sclerosis
P14 - Poster Session 14 (11:45 AM-12:45 PM)
12-011

The aim is to analyze all files centralized as Radiologically Isolated Syndrome (RIS) and collect clinical, biological, and imaging data to promote research.

Since the first published 2009 RIS diagnostic criteria, our consortium has collected cases with incidental findings on the brain or spinal cord MRI suggestive of demyelinating disease without Multiple Sclerosis (MS) signs and symptoms.

We collected prospectively all cases addressed for suspicion of RIS in 35 MS clinics, and a double-blind MRI reading agrees for RIS status on imaging and patient medical history. These cases are classified into three groups: (1) 2009 RIS subjects fulfilling at least three out of four criteria for Dissemination in Space (DIS); (2) Suspected-RIS subjects fulfilling only one or two criteria for DIS (PRERIS); (3) NON-RIS.

This cohort contains 617 files in October 2021: 452 (75%) Women, Mean age at inclusion 38 years [10 -71]. On the 467 confirmed RIS cases: during the mean follow-up of 15.4 months [0-203], 103 (22%) have converted clinically. Meantime for the seminal event: 40.8 months [1.5 – 196.9] after the index MRI.

On the 150 PRERIS cases: during the mean follow-up of 35.3 months [0.1-180], 26 (17.3%) have converted clinically. Meantime for the seminal event was 54.1 months [3.2-233] after the index MRI.

Of the 124 PRERIS (82.7%) who have not converted clinically, 58 (46.8%) have MRI DIT and eventually fulfilled the 2009 RIS criteria, and 66 (53.2%) are still classified as PRERIS.

Fifty-nine cases were classified after adjudication as NON-RIS for either suggestive history of demyelinating disease (9), abnormalities suggestive of another condition (12), or non-specific lesions (38).

This cohort demonstrates that 1/ Some RIS subjects can rapidly present clinical event 2/PRERIS subjects can evolve either to 2009 RIS or to MS 3/ Misdiagnosis is possible, and criteria sensibility should not overrule specificity.

Authors/Disclosures
Cassandre Landes-Chateau, PhD
PRESENTER
Mrs. Landes-Chateau has received research support from University Cote d'Azur.
Lydiane Mondot Lydiane Mondot has nothing to disclose.
Mikael Cohen (Hopital Pasteur) Mikael Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Roche, Merck, Ad scientiam, Novartis, Alexion, BMS.
No disclosure on file
Helene Zephir (Hospital Roger Salengro) Helene Zephir has received personal compensation in the range of $0-$499 for serving as a Consultant for BIogen Idec. Helene Zephir has received personal compensation in the range of $0-$499 for serving as a Consultant for novartis. Helene Zephir has received personal compensation in the range of $0-$499 for serving as a Consultant for BMS. Helene Zephir has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion.
Celine Louapre (Hôpital Pitié Salpêtrière, APHP) Celine Louapre has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Celine Louapre has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Celine Louapre has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Celine Louapre has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Celine Louapre has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Oculis.
Francoise Durand Dubief (Hopital Pierre Wertheimer) The institution of Francoise Durand Dubief has received research support from ARSEP.
Clarisse Carra-Dalliere No disclosure on file
Eric Thouvenot, MD, PhD (CHU De Nimes - Hopital Caremeau) Dr. Thouvenot has received personal compensation in the range of $0-$499 for serving as a Consultant for Biogen. Dr. Thouvenot has received personal compensation in the range of $0-$499 for serving as a Consultant for Merck. Dr. Thouvenot has received personal compensation in the range of $0-$499 for serving as a Consultant for Teva. Dr. Thouvenot has received personal compensation in the range of $0-$499 for serving as a Consultant for Novartis. Dr. Thouvenot has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Thouvenot has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Thouvenot has received research support from Biogen. The institution of Dr. Thouvenot has received research support from Novartis. The institution of Dr. Thouvenot has received research support from Roche.
Emmanuelle Le Page (CHR Pontchaillou) Emmanuelle Le Page has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for MERCK. Emmanuelle Le Page has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Aurelie Ruet (Hopital Pellegrin) The institution of Aurelie Ruet has received research support from BIOGEN. The institution of Aurelie Ruet has received research support from ROCHE. The institution of Aurelie Ruet has received research support from SANOFI GENZYME. The institution of Aurelie Ruet has received research support from BMS. Aurelie Ruet has received personal compensation in the range of $0-$499 for serving as a Board member with Horizon therapeutic. Aurelie Ruet has received personal compensation in the range of $0-$499 for serving as a Board member with Alexion. Aurelie Ruet has received personal compensation in the range of $0-$499 for serving as a Speaker meeting with BIOGEN. Aurelie Ruet has received personal compensation in the range of $500-$4,999 for serving as a Speaker meeting with MERCK. Aurelie Ruet has received personal compensation in the range of $0-$499 for serving as a Speaker meeting with Sanofi Genzyme.
No disclosure on file
Nathalie Derache (Hopital Cote De Nacre) Nathalie Derache has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MERCK. Nathalie Derache has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MERCK. Nathalie Derache has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS.
Pierre Clavelou, MD, PhD (Hopital Gabriel Montpied) Dr. Clavelou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Clavelou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Clavelou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck.
Thibault Moreau Thibault Moreau has nothing to disclose.
Olivier Casez, MD (CHU De Grenoble) Dr. Casez has nothing to disclose.
Olivier F. Gout, MD (Hôpital Fondation A de Rothschild) Dr. Gout has nothing to disclose.
Jerome De Seze Jerome De Seze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma. Jerome De Seze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma. Jerome De Seze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma. Jerome De Seze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma. Jerome De Seze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma. Jerome De Seze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma. Jerome De Seze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma. Jerome De Seze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma.
Jonathan Ciron, MD (CHU Toulouse) Jonathan Ciron, MD has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Jonathan Ciron, MD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Jonathan Ciron, MD has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Jonathan Ciron, MD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS - Celgene. Jonathan Ciron, MD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion.
No disclosure on file
Bertrand Bourre Bertrand Bourre has nothing to disclose.
Laurent Magy, MD (Chru Dupeytren, Neurology Dept) No disclosure on file
Philippe Cabre No disclosure on file
Jean Pelletier, MD, PhD (Dpt of Neurology, CHU Timone) Dr. Pelletier has nothing to disclose.
Marc Debouverie, MD (Hospital Central) Dr. Debouverie has nothing to disclose.
Bruno Stankoff, MD, PhD (Hopital De La Pitie Salpetriere) The institution of Bruno Stankoff, MD, PhD has received research support from Roche, Sanofi, Serono . The institution of Bruno Stankoff, MD, PhD has received research support from Novartis.
Alain Creange (Hopital Henri Mondor) Alain Creange has nothing to disclose.
Ombeline Fagniez, MD Ombeline Fagniez, MD has nothing to disclose.
Corinne Pottier Corinne Pottier has nothing to disclose.
Jean Philippe Neau, MD No disclosure on file
Jean-Phillippe Camdessanche Jean-Phillippe Camdessanche has nothing to disclose.
Carole Henry Carole Henry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for biogen. Carole Henry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for novartis.
Stephane Beltran Stephane Beltran has nothing to disclose.
Anne Marie Guennoc Anne Marie Guennoc has nothing to disclose.
Ayman P. Tourbah (Department of Neurology University Hospital Raymond Poincaré) No disclosure on file
Fatai Radji, MD (Neurologie Hopital Saint Esprit) Dr. Radji has nothing to disclose.
Nathalie Morel, MD (CH Annecy-Genevois) Dr. Morel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Morel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck Serono. Dr. Morel has received personal compensation in the range of $0-$499 for serving as a Consultant for Sanofi-Adventis.
No disclosure on file
Abdullatif Al Khedr (CHRU Amiens Nord) No disclosure on file
Aksel Siva, MD (Istanbul University Cerrahpasa School of Medicine) Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ali Raif Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanovel Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abdi Ibrahim Ilac - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono . The institution of Dr. Siva has received research support from Turkish MS Society. The institution of Dr. Siva has received research support from The Scientific and Technological Research Council Of Turkey - Health Sciences Research Grants.
Orhun H. Kantarci, MD Dr. Kantarci has nothing to disclose.
Daniel Pelletier, MD (Keck School of Medicine of USC) Dr. Pelletier has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Pelletier has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi Genzyme. Dr. Pelletier has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Pelletier has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Polpharma Biologics.
Darin T. Okuda, MD, FAAN (UT Southwestern Medical Center) Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cortechs AI. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Okuda has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Okuda has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave Bioscience. Dr. Okuda has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Pfizer. Dr. Okuda has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Zenas BioPharma. The institution of Dr. Okuda has received research support from Novartis. The institution of Dr. Okuda has received research support from Alexion. Dr. Okuda has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
No disclosure on file